Tesamorelin

Effects documented in the literature

Tesamorelin is a stabilized analog of human GHRH (1-44) protected against DPP-IV degradation by an N-terminal trans-3-hexenoyl group. Studies (PMID 20554713, PMID 18690162, JAMA fullarticle/1889139) showed that Tesamorelin binds to the GHRH-R receptor of pituitary somatotropic cells, activating the Gαs → cAMP → PKA pathway and stimulating physiological pulsatile release of endogenous GH. Downstream, hepatic IGF-1 increases. At the body level, clinical work (HIV population with lipodystrophy) documented a selective and significant reduction in visceral adipose tissue (−18% over 26 weeks), without loss of subcutaneous tissue or major effect on blood glucose or insulin sensitivity. The studies also describe a favorable modulation of lipid markers (decreased triglycerides). These data come from the scientific literature and are provided strictly for informational purposes in a research context. This product is not intended for veterinary, diagnostic or therapeutic use and is not recommended for any use outside a scientific, professional and research setting. [1][2][3]